One of these, published in 1993, was a US National Toxicology Program report, which found that cosmetic grade talc containing no asbestos-like fibres was correlated with tumor formation in rats forced to inhale talc for 6 hours a day, five days a week over at least 113 weeks. A 1971 paper found particles of talc embedded in 75% of the ovarian tumors studied. Research published in 1995 and 2000 concluded that it was plausible that talc could cause ovarian cancer, but no conclusive evidence was shown. The Cosmetic Ingredient Review Expert Panel concluded in 2015 that talc, in the concentrations currently used in cosmetics, is safe. In 2018, Health Canada issued a warning, advising against inhaling talcum powder or using it in the female perineal area. Industrial grade
In the United States, the Occupational Safety and Health Administration and National Institute for Occupational Safety and Health have set occupational exposure limits to respirable talc dusts at 2 mg/m3 over an eight-hour workday. At levels of 1000 mg/m3, inhalation of talc is considered immediately dangerous to life and health. Food grade
The United States Food and Drug Administration considers talc (magnesium silicate) generally recognized as safe (GRAS) to use as an anticaking agent in table salt in concentrations smaller than 2%. Association with asbestos
One particular issue with commercial use of talc is its frequent co-location in underground deposits with asbestos ore. Asbestos is a general term for different types of fibrous silicate minerals, desirable in construction for their heat resistant properties.
Common mild side-effects include an elevated heart rate, muscle cramps, and gastric upset (including heartburn and diarrhea).Symptoms of overdose in particular include: collapse into a seizure; chest pain (possible precursor of a heart attack); fast, pounding heartbeat, which may cause raised blood pressure (hypertension); irregular heartbeat (cardiac arrhythmia), which may cause paradoxical lowered blood pressure (hypotension); nervousness and tremor; headache; dizziness and nausea/vomiting; weakness or exhaustion (medical fatigue); dry mouth; and insomnia.Rarer side effects may indicate a dangerous allergic reaction. These include: paradoxical bronchospasm (shortness of breath and difficulty breathing); skin itching, rash, or hives (urticaria); swelling (angioedema) of any part of the face or throat (which can lead to voice hoarseness), or swelling of the extremities. Pharmacology
Mechanism of action
Activation of β2 adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of 3,5-cyclic adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn, inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. Levosalbutamol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways. Levosalbutamol acts as a functional agonist that relaxes the airway irrespective of the spasmogen involved, thereby protecting against all bronchoconstrictor challenges.